Buyside View XIX: Commercial Risk

BioCentury's 19th Annual Buyside View finds money managers entering 2011 cautiously optimistic about biotech's prospects, particularly as some of the high-profile compounds have already reported some data, lowering risk.

Amidst the optimism is a fair amount of caution, however, as a number of important events involve commercial product launches - an area where the sector has recently failed to meet expectations. Products under the microscope will include Prolia/Xgeva denosumab from Amgen Inc. and Provenge sipuleucel-T from Dendreon Corp...